Dr. Prakasha Kempaiah

Division of Infectious Diseases
Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224

Associate Consultant

Email: Kempaiah.Prakasha@mayo.edu

Qualification

2006 Ph.D., Institute of Human Genetics, Univ. of Goettingen, Germany

2000 M.Sc., Department of Biotechnology, Univ. of Agril Sciences,  India

1997 B.Sc., University of Agril Sciences, Bangalore, India

Publications (Selected)

1. Gupta Y, Maciorowski D, Zak SE, Kulkarni CV, Herbert AS, Durvasula R, Fareed J, Dye JM, Kempaiah P. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. Int J Biol Macromol. 2021 Apr 26;183:203-212. PMID: 33915212.
2. Gupta Y, Goicoechea S, Pearce CM, Mathur R, Romero JG, Kwofie SK, Weyenberg MC, Daravath B, Sharma N, Poonam, Akala HM, Kanzok SM, Durvasula R, Rathi B, Kempaiah P. The emerging paradigm of calcium homeostasis as a new therapeutic target for protozoan parasites. DOI: 10.1002/med.21804. Medicinal Research Reviews. 2021 Apr 13;1–27. PMID: 33851452.
3. Rathi B, Kempaiah P. Bioactive Chemical Entities: Pre-clinical and Clinical Aspects - Part-II. Curr Top Med Chem. 2020;20(8):606. doi: 10.2174/156802662008200331074457. PMID:32362271.
4. Kubicek-Sutherland JZ, Xie G, Shakya M, Dighe PK, Jacobs LL, Daligault H, Davenport K, Stromberg LR, Stromberg ZR, Cheng Q, Kempaiah P, Ong'echa JM, Otieno V, Raballah E, Anyona S, Ouma C, Chain PSG, Perkins DJ, Mukundan H, McMahon BH, Doggett NA. Comparative genomic and phenotypic characterization of invasive non-typhoidal Salmonella isolates from Siaya, Kenya. PLoS Negl Trop Dis.15(2):e0008991. 2021 Feb. PMID: 33524010 .
5. Kumar S, Sharma PP, Upadhyay C, Kempaiah P, Rathi B and Poonam. Exceptional multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by Molecular Docking and MD simulation methodologies. Feb 2021. Methods. 2021 Feb 24:S1046-2023(21)00062-1. PMID: 33639316.
6. Iandiorio MJ, Fazio JC, Kempaiah P, Durvasula R, van Regenmortel MHV, Rivas AL. Personalized and dynamic antibiograms-an exploration in seven infectious syndromes. MedRxiv. doi: https://doi.org/10.1101/2021.01.22.21249954. Jan 2021.
7. Hittner JB, Fasina FO, Hoogesteijn AL PiccininiR, Kempaiah P, Rivas AL. Early and massive testing saves lives: COVID-19 related infections and deaths in the United States during March of 2020. April 2020. BIORXIV/2020/073692. (doi: https://doi.org/10.1101/2020.05.14.20102483). Biomedical and Environmental Sciences. Jan 2021.
8. Gupta Y, Maciorowski D, Zak SE, Jones KA, Kathayat RS, Azizi SA, Mathur R, Pearce CM, Ilc DJ, Husein H, Herbert AS, Bharti A, Rathi B, Durvasula R, Becker DP, Dickinson BC, Dye JM and Kempaiah P. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening and in vitro assays. Methods. Jan 2021. 13:S1046-2023(21)00015-3. PMID: 33453392.
9. Rivas AL, Hoogesteijn AL, Hittner JB, van Regenmortel MHV, Kempaiah P, Vogazianos P, Antoniades A, Ioannidis A, Febles JL, Fasina FO. Toward a COVID-19 testing policy: where and how to test when the purpose is to isolate silent spreaders. MedRxiv. doi: https://doi.org/10.1101/2020.12.22.20223651. December 24, 2020.
10. Maciorowski D, Gupta Y, Mohammed A. Alsawi, David J. IIc, Mohama S, Lodolce JP, Kempaiah P. Molecular Insights Into SARS-CoV-2 Pathobiology: Dissecting the Interplay Between Cellular-Innate Immunity and Immune Evasion. DOI: 10.1615/CritRevImmunol.2020035855. Critical Reviews™ in Immunology 40 (6). pages 485-496. Nov 2020. PMID: 33900693.
11. Sharma N, Gupta Y, Snigdha S, Prateek P, Mohammed S, Raman M, Mohammad K, Maria G, Vladimir P, Vinoth R, Poonam S, Kempaiah P, Agam S, Rathi B. Multistage Antiplasmodial Activity of Hydroxyethylamine Compounds, In vitro and In vivo Evaluations. Royal Society of Chemistry Advances. DOI: 10.1039/D0RA03997G. Sept 2020,10, 35516-35530.
12. Maciorowski D, Idrissi SZE, Gupta Y, Medernach BJ, Burns MB, Becker DP, Durvasula R, Kempaiah P. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments Against COVID-19. SLAS Discovery. Sept 2020. PMID: 32942923.
13. Kumar S, Goicoechea S, Kumar S, Pearce CM, Durvasula R, Kempaiah P, Rathi B, Poonam. Oseltamivir analogs with potent anti-influenza virus activity. Drug Discovery Today. 2020 Jun 15: S1359-6446(20)30229-4. PMID:32554062.
14. Gupta Y, Maciorowski D, Mathur R, Pearce CM, Ilc DJ, Husein H, Bharti A, Becker DP, Brijesh R, Bradfute SB, Durvasula R, Kempaiah, P. Revealing SARS-CoV-2 Functional Druggability Through Multi-Target CADD Screening of Repurposable Drugs. Preprints.org, May 2020, 2020050199 DOI: 10.20944/preprints202005.0199.v1.
15. Kumar S, Sharma PP, Shankar U, Kumar D, Joshi SK, Pena L, Durvasula R, Kumar A, Kempaiah P, Poonam, and Rathi B. Discovery of New Hydroxyethylamine Analogs against 3CLpro Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure–Activity Relationship Studies. ACS J Chem Inf Model. 2020 Jun 18:acs.jcim.0c00326. PMID: 32551639.